PI3K and mix: Infinity gets back assets and cash from Mundipharma
This article was originally published in Scrip
Executive Summary
In an effort to retain more value from its phosphoinositide-3-kinase (PI3K), fatty acid amide hydrolase (FAAH) and early discovery programs, Infinity Pharmaceuticals traded its partnership with UK-based Mundipharma International for an equity investment by Mundipharma's privately-held US subsidiary Purdue Pharma.